secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0000012208-25-000009
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad discloses Sartorius AG FY2024 results: revenue €3.38B, net profit €137.4M
--------------------------------------------------------------------------------

- Sartorius AG reported FY2024 sales revenue of €3,380.7M, gross profit €1,524.4M, EBIT €392.6M.
- Net profit for FY2024 was €137.4M; operating cash flow €976.2M, investing cash flow -€425.8M.
- As of Dec 31, 2024, Sartorius had total assets €10,103.0M, total liabilities €6,205.2M, equity €3,897.8M.
- Bio-Rad does not assume responsibility for Sartorius's publicly disclosed figures; refers to Sartorius's annual report.
- Update relates to Bio-Rad's Investment in Sartorius AG section of its 2024 10-K filed Feb 14, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000009/0000012208-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000009/bio-20250221.htm
  HTML page:      https://secwatch.observer/filing/0000012208-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer